XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.1

Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - Sanofi Collaboration Agreement, Antibody $ in Millions	3 Months Ended
	Mar. 31, 2025 USD ($)
Disaggregation of Revenue [Line Items]
Percentage share of profits to reimburse collaborating party	20.00%
Contingent reimbursement obligation	$ 1,453
Starting share of profits outside the United States, based on sales, for collaborating party	65.00%
Starting share of profits outside the United States, based on sales, for Company	35.00%
Ending share of profits outside the United States, based on sales, for collaborating party	55.00%
Ending share of profits outside the United States, based on sales, for Company	45.00%
Minimum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party	80.00%
Percentage share of profits to reimburse collaborating party	30.00%
Maximum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party	100.00%
Percentage share of profits to reimburse collaborating party	50.00%

X

- Definition

The Company's total contingent reimbursement obligation to its collaboration partner for development expenses previously funded by its collaboration partner.

+ References

No definition available.

+ Details

Name:	regn_ContingentReimbursementObligation
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the collaborating party.

+ References

No definition available.

+ Details

Name:	regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty
Namespace Prefix:	regn_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the Company.

+ References

No definition available.

+ Details

Name:	regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany
Namespace Prefix:	regn_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs

+ References

No definition available.

+ Details

Name:	regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
Namespace Prefix:	regn_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of Trial Costs Required To Be Funded By Collaborating Party

+ References

No definition available.

+ Details

Name:	regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
Namespace Prefix:	regn_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the collaborating party.

+ References

No definition available.

+ Details

Name:	regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty
Namespace Prefix:	regn_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the Company.

+ References

No definition available.

+ Details

Name:	regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany
Namespace Prefix:	regn_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: